Myriad Genetics ends CCO Brian Donnelly role; severance disclosed

Myriad Genetics finalized a separation agreement with former Chief Commercial Officer Brian Donnelly, including a $1,322,294 lump-sum severance and accelerated vesting provisions, effective October 14, 2026 subject to revocation.